Good morning members,
Our new biotech alert of the week is Actinium Pharmaceuticals (NYSE-MKT: ATNM)
Key Highlights
-ATNM- "On track to submit the Iomab-B IND filing in the fourth quarter of 2015"
-Institutional ownership on the rise- follow the smart money
-Lower end of the 52 week range
-An absolutely great article about one of ATNM's drug candidates and what they are trying to accomplish: http://www.bionapcfa.com/2015/11/actinium-pharmaceuticals-platform.html?m=1
Getting their house in order
An excerpt from the cover letter of a 14A filing on November, 13th 2015, should get you started on your due diligence and give everyone a good idea of why we like ATNM right now.
Dear Actinium Shareholders,
"Above all else, we wish to thank all our shareholders, new and old, for their faith in our ability to execute on our strategy and generate shareholder value. As outlined in our letter to you in July, we acknowledge that we have faced challenges this year, specifically with manufacturing process and scale-up issues pertaining to Iomab TM -B. We are pleased to have overcome these obstacles and now with these challenges behind us and our organization stronger than ever before, we are eager to embark on a new era for Actinium. We have made significant strides with Iomab-B and are on track to file the IND by year end. With respect to Actimab-A, we are excited to be near the conclusion of the Phase 1 portion of the clinical trial, which will be highlighted at the 57 th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida on December 4 - 8, 2015. We are eager to begin the Phase 2 portion of the trial as we are very well-positioned competitively. We look forward to the future with confidence in our strategy as we progress into 2016. We will strive to deliver sustainable results that will drive growth and generate shareholder value as we continue to drive the business forward in 2016 and beyond.
Key Achievements in 2015"
• On track to submit the Iomab-B IND filing in the fourth quarter of 2015
• Completed the majority of the Phase 1 clinical trial for Actimab-A, the final three confirmatory patients are now enrolling which will enable the Phase 2 trial to start in 2016
• Actimab-A’s positive results imply leadership position in the renewed race for CD-33 targeting drugs in AML
• Started work on an exciting new indication for one of our drug candidates with proof of concept studies expected in 2016
• Successfully labeled an antibody with Actinium-225 creating an exciting new pipeline candidate with broad hematology applications
• Strengthened our development team with key senior level hires in place ahead of the upcoming Phase 3 clinical trial for Iomab-B and Phase 2 trial for Actimab-A next year
***Much Anticipated IND Filing to Enable Initiation of Iomab-B’s Single, Pivotal, Phase 3 Clinical Trial in 2016
In 2015, we successfully addressed our manufacturing challenges, bolstered our development team in key areas and established a clear regulatory pathway for Iomab-B. In addition, we further strengthened our intellectual property portfolio with a provisional patent application for infusion administration of Iomab-B. These achievements give us great confidence as we look past our planned fourth quarter IND filing toward to the upcoming pivotal, Phase 3 clinical trial. We have hired and will continue to hire key professionals to our clinical, project management, manufacturing, quality control and regulatory teams to ensure that we execute the Iomab-B trial in the most efficient and timely manner. With these new members firmly on board, we are confident in our ability to execute and look forward to providing you, our shareholders, with regular updates on our progress as we seek to obtain regulatory approval for Iomab-B and deliver this important, potentially breakthrough therapy to patients.
Full 14A filing- http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11007049
Actinium Pharmaceuticals Inc (NYSE: ATNM) Check the company website for investor presentation and more in-depth information about their drug pipeline.
http://www.actiniumpharma.com
*Actinium Pharmaceuticals (ATNM) is a biopharmaceutical company specializing in the development of cancer drugs. They are the leading biotechnology company developing alpha particle linked antibodies to treat cancer.
Current- $2.17/share
52 week range- $1.52 - $6.65
Chart- http://stockcharts.com/h-sc/ui?s=atnm
We will be back with much more soon. I think the timing is perfect here.
The Team |
|
|
